NCT06881784Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Study sponsor: Revolution Medicines, Inc. · RVMD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-12-01Estimated

Enrollment · participants590Estimated

Source updated2026-08-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-29 · 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Progression free survival (PFS) per ~~Investigator~~ in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population

+ After

Measure: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population

Planned enrollment increased by 170 participants

− Before

~~420 participants (planned)~~

+ After

590 participants (planned)

Check registry source

Posted 2025-10-22 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population Measure: Overall survival (OS) in the RAS G12X-C population

+ After

Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population

Check registry source

Study details

Conditions studied

NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer)

Treatments or interventions studied

daraxonrasibDrug
docetaxelDrug

Primary outcomes · main study measures

Read the study measures

measure: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C); description: PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.; timeFrame: Up to approximately 4 years; measure: Overall survival (OS) in the RAS G12X-C population; description: OS is defined as the time from randomization until death from any cause.; timeFrame: Up to approximately 4 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history